Lack of influence of the COX inhibitors metamizol and diclofenac on platelet GPIIb/IIIa and P-selectin expression in vitro

BMC Anesthesiology

Dirk Scheinichen¹  Holger-Andreas Elsner²  Rodin Osorio¹  Björn Jüttner¹  Werner Gröschel¹  Karsten Jaeger¹  Siegfried Piepenbrock¹ 

[1] Department of Anesthesiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany

[2] Department of Transfusion Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany

关键词: flow cytometry;    GPIIb/IIIa;    P-selectin;    platelet;    metamizol;    diclofenac;   

Others  :  1085186
DOI  :  10.1186/1471-2253-4-4

 received in 2003-10-01, accepted in 2004-04-23,  发布年份 2004

【 摘 要 】

Background

The effect of non-steroidal anti-inflammatory drugs (NSAIDs) for reduced platelet aggregation and thromboxane A₂ synthesis has been well documented. However, the influence on platelet function is not fully explained. Aim of this study was to examine the influence of the COX-1 inhibiting NSAIDs, diclofenac and metamizol on platelet activation and leukocyte-platelet complexes, in vitro. Surface expression of GPIIb/IIIa and P-selectin on platelets, and the percentage of platelet-leukocyte complexes were investigated.

Methods

Whole blood was incubated with three different concentrations of diclofenac and metamizol for 5 and 30 minutes, followed by activation with TRAP-6 and ADP. Rates of GPIIb/IIIa and P-selectin expression, and the percentage of platelet-leukocyte complexes were analyzed by a flow-cytometric assay.

Results

There were no significant differences in the expression of GPIIb/IIIa and P-selectin, and in the formation of platelet-leukocyte complexes after activation with ADP and TRAP-6, regarding both the time of incubation and the concentrations of diclofenac and metamizol.

Conclusions

Accordingly, the inhibitory effect of diclofenac and metamizol on platelet aggregation is not related to a reduced surface expression of P-selectin and GPIIb/IIIa on platelets.

【 授权许可】

   
2004 Scheinichen et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Peters MJ, Heyderman RS, Hatch DJ, Klein NJ: Investigation of platelet-neutrophil interactions in whole blood by flow cytometry. J Immunol Meth 1997, 209:125-135.
• [2]Peters MJ, Dixon G, Kotowicz KT, Hatch DJ, Heyderman RS, Klein NJ: Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing. Br J Haematol 1999, 106:391-399.
• [3]Cramer EM, Savidge GF, Vainchenker W, Berndt MC, Pidard D, Caen JP, Masse JM, Breton-Gorius J: Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes. Blood 1990, 75:1220-1227.
• [4]Liu YK, Nemoto A, Fang Y, Uemura T: The binding ability to matrix proteins and the inhibitory effects on cell adhesion of synthetic peptides derived from a conserved sequence of integrins. J Biochem 1997, 121:961-968.
• [5]Gawaz M, Dickfeld T, Bogner C, Fateh-Moghadam S, Neumann FJ: Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 1997, 23:379-385.
• [6]Evangelista V, Manarini S, Rotondo S, Martelli N, Polischuk R, McGregor JL, de Gaetano G, Cerletti C: Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: Evidence of adhesion cascade and cross talk between P-selectin and the beta 2 integrin CD11b/CD18. Blood 1996, 88:4183-4194.
• [7]Vane JR: The mechanism of action of anti-inflammatory drugs. In In Advances in eicosanoid research. Edited by Serhan CN, Perez HD. Berlin Heidelberg: Springer-Verlag; 2000:1-23.
• [8]Schafer AI: Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 1999, 106(Supl 5B):25S-35S.
• [9]Schmidt A, Bjorkman S, Akeson J: Preoperative rectal diclofenac versus paracetamol for tonsillectomy: effects on pain and blood loss. Acta Anaesthesiol Scand 2001, 45:48-52.
• [10]Perttunen K, Kalso E, Heinonen J, Salo J: IV diclofenac in post-thoracotomy pain. Br J Anaesth 1992, 68:474-480.
• [11]Laitinen J, Nuutinen LS, Puranen J, Ranta P, Salomaki T: Effect of a non-steroidal anti-inflammatory drug, diclofenac, on haemostasis in patients undergoing total hip replacement. Acta Anaesthesiol Scand 1992, 36:486-489.
• [12]Geisslinger G, Peskar BA, Pallapies D, Sittl R, Levy M, Brune K: The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. Thromb Haemost 1996, 76:592-597.
• [13]Eldor A, Zylber-Katz E, Levy M: The effect of oral administration of dipyrone on the capacity of blood platelets to synthesize thromboxane A2 in man. Eur J Clin Pharmacol 1984, 26:171-176.
• [14]Golanski J, Pietrucha T, Baj Z, Greger J, Watala C: Molecular insight into anticoagulant-induced spontaneous activation of platelets in whole blood: Various anticoagulants are not equal. Thromb Res 1996, 83:199-216.
• [15]Failli P, Cecchi E, Tosti-Guerra C, Mugelli A, Laffi G, Zilletti L, Giotti A: Effect of some cyclooxygenase inhibitors on the increase in guanosine 3':5'-cyclic monophosphate induced by NO-donors in human whole platelets. Br J Pharmacol 1998, 123:1457-1463.
• [16]Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ: Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000, 40:1109-1120.
• [17]Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C: Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 1997, 48:623-631.
• [18]Bozzo J, Escolar G, Hernandez MR, Galan AM, Ordinas A: Prohemorrhagic potential of dipyrone, ibuprofen, ketorolac, and aspirin: mechanisms associated with blood flow and erythrocyte deformability. J Cardiovasc Pharmacol 2001, 38:183-190.
• [19]Abbate R, Pinto S, Gori AM, Paniccia R, Coppo M, Neri Serneri GG: Activity of dipyrone on intraplatelet arachidonic acid metabolism: an in vitro study. Pharmacological Research 1989, 21:43-50.
• [20]Holmsen H: Significance of testing platelet functions in vitro. Eur J Clin Invest 1994, 24(Suppl 1):3-8.
• [21]Cronberg S, Wallmark E, Soderberg I: Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 1984, 33:155-159.
• [22]Eldor A, Polliack G, Vlodavsky I, Levy M: Effects of dipyrone on prostaglandin production by human platelets and cultured bovine aortic endothelial cells. Thromb Haemostas 1983, 49:132-137.
• [23]Domínguez-Jiménez C, Díaz-González F, González-Álvaro I, Cesar JM, Sánchez-Madrid F: Prevention of αIIbβ3 activation by non-steroidal anti-inflammatory drugs. FEBS Lett 1999, 446:318-322.
• [24]Andrioli G, Lussignoli S, Gaino S, Benoni G, Bellavite P: Study on paradoxical effects of NSAIDs on platelet activation. Inflammation 1997, 21:519-530.
• [25]Nyby MD, Sasaki M, Ideguchi Y, Wynne HE, Hori MT, Berger ME, Golub MS, Brickman AS, Tuck ML: Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation. J Pharmacol Exp Ther 1996, 278:503-509.
• [26]Fonlupt P, Croset M, Lagarde M: 12-HETE inhibits the binding of PGH2/TXA2 receptor ligands in human platelets. Thromb Res 1991, 63:239-248.
• [27]Cortelazzo S, Marchetti M, Orlando E, Falanga A, Barbui T, Buchanan MR: Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway. Am J Hematol 1998, 57:277-282.
• [28]Saeed SA, Afzal MN, Shah BH: Dual effects of nimesulide, a COX-2 inhibitor, in human platelets. Life Sciences 1998, 63:1835-1841.